Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation
- 3 April 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (486) , eaav0537
Abstract
Long-term cotrimoxazole prophylaxis reduces mortality and morbidity in HIV infection, but the mechanisms underlying these clinical benefits are unclear. Here, we investigate the impact of cotrimoxazole on systemic inflammation, an independent driver of HIV mortality. In HIV-positive Ugandan and Zimbabwean children receiving antiretroviral therapy, we show that plasma inflammatory markers were lower after randomization to continue (n = 144) versus stop (n = 149) cotrimoxazole. This was not explained by clinical illness, HIV progression, or nutritional status. Because subclinical enteropathogen carriage and enteropathy can drive systemic inflammation, we explored cotrimoxazole effects on the gut microbiome and intestinal inflammatory biomarkers. Although global microbiome composition was unchanged, viridans group Streptococci and streptococcal mevalonate pathway enzymes were lower among children continuing (n = 36) versus stopping (n = 36) cotrimoxazole. These changes were associated with lower fecal myeloperoxidase. To isolate direct effects of cotrimoxazole on immune activation from antibiotic effects, we established in vitro models of systemic and intestinal inflammation. In vitro cotrimoxazole had modest but consistent inhibitory effects on proinflammatory cytokine production by blood leukocytes from HIV-positive (n = 16) and HIV-negative (n = 8) UK adults and reduced IL-8 production by gut epithelial cell lines. Collectively we demonstrate that cotrimoxazole reduces systemic and intestinal inflammation both indirectly via antibiotic effects on the microbiome and directly by blunting immune and epithelial cell activation. Synergy between these pathways may explain the clinical benefits of cotrimoxazole despite high antimicrobial resistance, providing further rationale for extending coverage among people living with HIV in sub-Saharan Africa.Keywords
Funding Information
- Wellcome Trust (093768/Z/10/Z)
- Wellcome Trust (108065/Z/15/Z)
- Canadian Institutes of Health Research
- Medical Research Council (G0300400)
- Medical Research Council (G1001190)
- Medical Research Council (MC_UU_12023/26)
- Department for International Development, UK Government
- the Wellcome Trust and the Royal Society (206225/Z/17/Z)
This publication has 64 references indexed in Scilit:
- Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trialThe Lancet, 2013
- Metabolic Reconstruction for Metagenomic Data and Its Application to the Human MicrobiomePLOS Computational Biology, 2012
- Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individualsJournal of Clinical Investigation, 2012
- Minocycline Inhibition of Monocyte Activation Correlates with Neuronal Protection in SIV NeuroAIDSPLOS ONE, 2011
- Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV InfectionThe Journal of Infectious Diseases, 2011
- It's Not Easy Being Green: the Viridans Group Streptococci, with a Focus on Pediatric Clinical ManifestationsJournal of Clinical Microbiology, 2010
- Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohortThe Lancet, 2010
- Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV InfectionPLOS Medicine, 2008
- Microbial translocation is a cause of systemic immune activation in chronic HIV infectionNature Medicine, 2006
- VEGAN, a package of R functions for community ecologyJournal of Vegetation Science, 2003